Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISG/AIEOP EW-1 in non-metastatic Ewing sarcoma
ISRCTN50580483Phase 3Completed
- Sponsor
- Italian Sarcoma Group
- Start
- Apr 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vincristine, doxorubicin, cyclophosphamide, ifosfamide, actinomycin D and 3 more in Ewing sarcoma (2 arms), sponsored by Italian Sarcoma Group. Primary endpoint: Overall survival. Started Apr 2009; status: completed.
02
Drugs
vincristinedoxorubicincyclophosphamideifosfamideactinomycin D
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on ISRCTN50580483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50580483.